Trop-2 PET scan for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial uses a special PET scan to find a protein called Trop-2 on your cancer cells. It helps doctors decide if a targeted treatment (Trop-2 ADC) might work for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced triple-negative breast cancer that has spread or cannot be removed by surgery.
- You are well enough to get out of bed and take care of yourself (ECOG score of 2 or less).
- Your blood counts and liver/kidney function are within safe limits.
- You have at least one tumor that can be measured on a scan.
- You agree to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies how well sacituzumab govitecan (a targeted cancer drug) works for metastatic breast cancer that is HER2-negative. The study focuses on real-world patient experiences and quality of life in Chinese patients.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
This trial tests a new imaging agent (99mTc-MY6349) to see if it can detect Trop2, a protein found on some breast cancer cells. It may help doctors better see and understand triple-negative breast cancer that has spread.
This trial tests a combination of two drugs—an antibody-drug conjugate that targets a protein on cancer cells and an immunotherapy that helps your immune system attack the tumor—for people with advanced triple-negative breast cancer that has already been treated. It aims to see if this combo can shrink tumors or slow the disease.
This trial tests a combination of two drugs—sacituzumab govitecan (a targeted chemotherapy) and toripalimab (an immunotherapy)—as the first treatment for advanced triple-negative breast cancer. The goal is to see if this pair works better than standard treatments, and to look for biomarkers that might predict who benefits most.
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.